HRTX
Heron TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
HRTX Profile
Heron Therapeutics, Inc.
A commercial-stage biotechnology company that develops therapeutics used in nausea and vomiting prevention, pain management, and to treat inflammation
100 Regency Forest Drive, Suite 300, Cary, North Carolina 27518
--
Heron Therapeutics, Inc. The company was founded in February 1983 in California as AMCO Polymerics Corporation (AMCO). AMCO changed its name to Advanced Polymer Systems in 1984 and was re-incorporated in Delaware in 1987. The company, which changed its name to AP Pharma in May 2001 to reflect its new pharmaceutical focus, is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve healthcare. The company's main focus is on its leading product candidate, APF 530, which was developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The company's core Biochronomer technology includes biocorrosive polymers designed to release drugs within a specified period of time, and its APF 530 and other product candidates are developed based on this technology. The company has completed more than 100 in vivo and in vitro studies, and the results show that the company's Biochronomer technology may be applicable to a variety of therapeutic areas, including prevention of nausea and vomiting, pain management, inflammation control and ophthalmic disease treatment. The company also completed comprehensive animal and human toxicology studies and concluded that its Biochronomer polymer is safe and well tolerated. In addition, the company's Biochronomer technology can be used to release drugs within days or months.
